Previous 10 | Next 10 |
WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that manage...
Gainers: Inotiv (NOTV) +41%. TScan Therapeutics (TCRX) +23%. SomaLogic (SLGC) +19%. Veru (VERU) +18%. Celularity (CELU) +17%. Losers: Opiant Pharmaceuticals (OPNT) -16%. Renovacor (RCOR) -15%. Embecta (EMBC) -7%. Wave Life Sciences (WVE) -5%. ...
WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that t...
Gainers: TScan Therapeutics (TCRX) +34%. Appian (APPN) +30%. CECO Environmental (CECE) +24%. AdaptHealth (AHCO) +22%. FibroGen (FGEN) +22%. Aurinia Pharmaceuticals (AUPH) +21%. Cara Therapeutics (CARA) +20%. Pro-Dex (PDEX) +19%. Y-mAbs Therapeutics (YMAB) +19%. Losers: Upstart Holdings (UPST)...
TScan Therapeutics press release (NASDAQ:TCRX): Q1 GAAP EPS of -$0.67 beats by $0.06. Revenue of $3.02M (+48.8% Y/Y) beats by $0.26M. Shares +1.67% PM. As of March 31, 2022, TScan Therapeutics had cash and cash equivalents of $140.8 million excluding $5.0 million of restricted cash. For fur...
Preclinical data to be presented at the American Society of Gene & Cell Therapy 25 th Annual Meeting; virtual KOL event following the conference Phase 1 umbrella trial for leukemia program on track to initiate in the first half of 2022 Ended the first qua...
WALTHAM, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the accepta...
The CFO trading anomaly is well documented to show abnormal returns among the most knowledgeable insiders. Leveraging the SEC Form 4 database shows there has not been a $1 million CFO share purchase in over 40 days and only 3 so far into 2022. "CFOs utilize more (superior) informa...
Gainers: Veru (VERU) +196%. Hoth Therapeutics (HOTH) +126%. Altamira Therapeutics (CYTO) +54%. Iveda Solutions (IVDA) +37%. VNET Group (VNET) +30%. SailPoint Technologies Holdings (SAIL) +29%. Castor Maritime (CTRM) +25%. Datto Holding (MSP) +21%. Axcella Health (AXLA) +16%. TScan Therapeutic...
WALTHAM, Mass., April 11, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appoi...
News, Short Squeeze, Breakout and More Instantly...
TScan Therapeutics Inc. Company Name:
TCRX Stock Symbol:
NYSE Market:
TScan Therapeutics Inc. Website:
2024-07-26 15:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-16 12:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-26 16:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...